title: Immune-checkpoint inhibitors in hematologic malignancies.
abstract: Immuno-checkpoint inhibitors are one of the most promising immunotherapies for various advanced cancers including hematologic malignancies. Recently, enhanced signaling of the PD-1/CTLA4 pathway has emerged as a critical mechanism by which tumors can escape the anti-tumor immune response. PD-1-blocking antibodies have been used to enhance immunity in several malignancies and obtain durable responses, especially in patients with heavily treated relapsed/refractory Hodgkin lymphoma. Currently, several clinical trials including single agent or combination therapies for hematologic malignancies, such as Hodgkin lymphoma, B-cell lymphomas and multiple myeloma, are ongoing. The results of ongoing and future clinical trials may establish a new treatment paradigm for hematologic malignancies.
authors.affiliation: Department of Hematology, National Cancer Center Hospital.
authors.forename: Dai
authors.initials: D
authors.lastname: Maruyama
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor